Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

He is treating his fluid retention with 100 mg of furosemide daily. He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about ...